Merck gets positive CHMP opinion for Keytruda as first-line treatment for dMMR colorectal cancer

Merck gets positive CHMP opinion for Keytruda as first-line treatment for dMMR colorectal cancer

Source: 
Pharmaceutical Business Review
snippet: 


Merck (known as MSD outside the US and Canada) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.